Xenon Pharmaceuticals Inc. (FRA:XP0)

Market Cap	2.80B
Revenue (ttm)	6.39M
Net Income (ttm)	-261.09M
Shares Out	n/a
EPS (ttm)	-3.31
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	12
Open	35.20
Previous Close	35.80
Day's Range	35.20 - 35.20
52-Week Range	25.00 - 39.20
Beta	n/a
RSI	43.47
Earnings Date	Feb 27, 2026

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada. Its product candidates include Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. The com...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1996
• Employees: 327
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: XP0

Financial Performance

Financial numbers in USD